{"id":3218,"date":"2013-07-11T06:30:00","date_gmt":"2013-07-11T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/interim-report-january-june-2013\/"},"modified":"2013-07-11T06:30:00","modified_gmt":"2013-07-11T06:30:00","slug":"interim-report-january-june-2013","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2013\/","title":{"rendered":"Interim report January – June 2013"},"content":{"rendered":"
US study has full number of patients and good clinical results presented for patients outside the USA<\/strong><\/div>\n

SIGNIFICANT EVENTS IN THE SECOND QUARTER<\/span><\/p>\n

\u2022 All the planned 42 + 42 patients have now been included in the clinical study of STEEN Solution\u2122 in the USA and the clinical results are very promising.<\/span><\/p>\n

\u2022 At the ISHLT conference in April, three leading clinics outside the USA (Toronto, Paris and Europe\u2019s largest lung transplant clinic in Vienna) presented very good clinical data for 112 patients using XVIVO Perfusion\u2019s product STEEN Solution\u2122. The results show that by using STEEN Solution\u2122 the clinics were able to save many lungs that had initially been assessed as unusable. The lungs were transplanted into patients in need, and the results were at least as good as for lungs initially deemed acceptable.<\/span><\/p>\n

\u2022 During the quarter, the company submitted its response to the FDA\u2019s supplementary questions regarding the application for marketing approval of STEEN Solution\u2122 on the US market. The FDA is expected to notify its decision in the third quarter.<\/span><\/p>\n

\u2022 At the end of June a total of 47 patients in the USA had been transplanted with lungs made available through the use of Steen Solution\u2122 and XVIVO\u2019s perfusion machine XPS\u2122.
<\/span><\/p>\n

FIRST HALF (JAN-JUN 2013)<\/span><\/p>\n

\u2022 Sales increased by 21 percent in local currency. Sales amounted to SEK 32.1 (27.8*) million, corresponding to an increase of 15 percent in SEK.<\/span><\/p>\n

\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 6.1 (9.2*) million, corresponding to an EBITDA margin of 19 percent.<\/span><\/p>\n

\u2022 Net income amounted to SEK 4.1 million, resulting in earnings per share of SEK 0.21.<\/span><\/p>\n

\u2022 Cash flow from operating activities was SEK 7.9 million.
<\/span><\/p>\n

SECOND QUARTER (APR \u2013 JUN 2013)<\/span><\/p>\n

\u2022 Sales increased by 18 percent in local currency. Sales amounted to SEK 15.8 (14.0*) million, corresponding to an increase of 12 percent in SEK.<\/span><\/p>\n

\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 2.4 (4.2*) million, corresponding to an EBITDA margin of 15 percent.<\/span><\/p>\n

\u2022 Net income amounted to SEK 1.7 million, resulting in earnings per share of SEK 0.09.<\/span><\/p>\n

\u2022 Cash flow from operating activities was SEK 3.9 million.
<\/span><\/p>\n

CONFERENCE CALL<\/span><\/p>\n

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Thursday, July 11, 2013.<\/span>
Telephone: +46 8 50336434 or +44 (0)20 1452 555566, enter code 98290392<\/span><\/p>\n

* Comparative figures for 2012 are Vitrolife\u2019s Transplantation segment such as it was reported in Vitrolife\u2019s reporting<\/span><\/span><\/span><\/span><\/p>\n<\/p>\n

\n

For further information please contact:
<\/span>
Magnus Nilsson, CEO, tel: 46 31 788 21 50, e-mail: magnus.nilsson@xvivoperfusion.com<\/span>
Christoffer Rosenblad, CFO, tel: 46 31\u00a0788 21 59, e-mail: christoffer.rosenblad@xvivoperfusion.com<\/a><\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and\/or the Financial Instruments Trading Act. The information was submitted for publication on\u00a0July 11, 2013\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

US study has full number of patients and good clinical results presented for patients outside the USA SIGNIFICANT EVENTS IN…<\/p>\n","protected":false},"template":"","class_list":["post-3218","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q2"],"acf":[],"yoast_head":"\nInterim report January - June 2013 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2013\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interim report January - June 2013 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"US study has full number of patients and good clinical results presented for patients outside the USA SIGNIFICANT EVENTS IN...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2013\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-june-2013\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-june-2013\\\/\",\"name\":\"Interim report January - June 2013 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-07-11T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-june-2013\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-june-2013\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-june-2013\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interim report January – June 2013\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim report January - June 2013 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2013\/","og_locale":"en_US","og_type":"article","og_title":"Interim report January - June 2013 - XVIVO","og_description":"US study has full number of patients and good clinical results presented for patients outside the USA SIGNIFICANT EVENTS IN...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2013\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2013\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2013\/","name":"Interim report January - June 2013 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-07-11T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2013\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2013\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2013\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Interim report January – June 2013"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}